Nature Search

Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors

Both environmental factors and genetic factors influence human immunity. Albert and colleagues leverage data from the Milieu Intérieur Consortium to comprehensively describe the effects of lifestyle, environment and genetics on human innate and adaptive immunity.

Etienne Patin
Milena Hasan
Matthew L. Albert
Research23 Feb 2018
Nature Immunology

Volume: 19, P: 302-314
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

Stephen J. Bagley
Arati S. Desai
Donald M. O’Rourke
Amendments and Corrections11 Jun 2025
Nature Medicine

Volume: 31, P: 3205
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

Bagley et al. conduct a phase 1 trial to study safety and tolerability of CAR T-EGFRvIII cells administered concomitantly with PD-1 inhibition via pembrolizumab in patients with glioblastoma and show tolerability, but without signs of efficacy.

Stephen J. Bagley
Zev A. Binder
Donald M. O’Rourke
Research12 Jan 2024
Nature Cancer

Volume: 5, P: 517-531
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

As presented at the 2025 ASCO Annual Meeting, intracerebroventricular infusion of bivalent CAR T cells targeting EGFR and IL-13Rα2 in patients with multifocal, recurrent glioblastoma was feasible and well tolerated, with the maximum tolerated dose identified, one patient with a partial response and one patient with durable stable disease.

Stephen J. Bagley
Arati S. Desai
Donald M. O’Rourke
Research01 Jun 2025
Nature Medicine

Volume: 31, P: 2778-2787
Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

Infusion of CD19-directed chimeric antigen receptor T cells into two patients with chronic lymphocytic leukaemia resulted in complete tumour remission and persistence of the infused cells more than ten years later.

J. Joseph Melenhorst
Gregory M. Chen
Carl H. June
Research02 Feb 2022
Nature

Volume: 602, P: 503-509
Author Correction: Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells

J. Joseph Melenhorst
Gregory M. Chen
Carl H. June
Amendments and Corrections07 Dec 2022
Nature

Volume: 612, P: E22
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

In a randomized phase 2 trial, sotigalimab, a CD40 agonist, did not significantly improve overall survival in patients with previously untreated metastatic pancreatic cancer when combined with chemotherapy or with nivolumab and chemotherapy. Multi-omic exploratory analyses provide insights into immunologic features associated with clinical benefit.

Lacey J. Padrón
Deena M. Maurer
Robert H. Vonderheide
ResearchOpen Access03 Jun 2022
Nature Medicine

Volume: 28, P: 1167-1177
Publisher Correction: Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors

Etienne Patin
Milena Hasan
Matthew L. Albert
Amendments and Corrections03 May 2018
Nature Immunology

Volume: 19, P: 645
CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer

A study of hospitalized patients infected with SARS-CoV-2 and who have liquid or solid cancer suggests that hematologic malignancy is an independent risk factor for mortality and that CD8⁺ T cells might limit infection in this setting irrespective of humoral immunity.

Erin M. Bange
Nicholas A. Han
Alexander C. Huang
Research20 May 2021
Nature Medicine

Volume: 27, P: 1280-1289

Search

Filter By:

Search

Quick links